洛匹那韦/利托那韦片联合干扰素α-2b雾化、胸腺素α1治疗新型冠状病毒肺炎13例  

Thirteen cases of COVID patients treated by the combination of lopinavir/ritonavir tablets,atomized interferonα-2b and thymosinα1

作　　者：郑宏波 苏海生 王山军 刘小莹 赵文轩 张瑞娟 王一龙 刘喆 刘海玲 ZHENG Hong-bo;SU Hai-sheng;WANG Shan-jun;LIU Xiao-ying;ZHAO Wen-xuan;ZHANG Rui-juan;WANG Yi-long;LIU Zhe;LIU Hai-ling(Xianyang Central Hospital,Xianyang 712000,China)

机构地区：[1]咸阳市中心医院,陕西咸阳712000

出　　处：《临床医学研究与实践》2020年第S01期36-38,共3页Clinical Research and Practice

摘　　要：目的研究洛匹那韦/利托那韦片联合干扰素α-2b雾化、胸腺素α1治疗新型冠状病毒肺炎(COVID-19)的临床效果。方法选择2020年1月至2020年2月我科室收治的13例COVID-19确诊患者,给予洛匹那韦/利托那韦片口服、干扰素α-2b雾化、胸腺素α1皮下注射。观察患者的治疗疗效、临床症状改善情况、治疗前、后实验室指标及HRCT评分变化情况。结果13例确诊患者均治愈出院,无一例重症发生,平均住院时间为15 d,平均退热时间为3 d,平均咳嗽明显减轻时间为5 d。患者LY、CRP、SAA、HRCT治疗前均明显异常;治疗后,患者的LY、CRP、SAA水平及HRCT评分均优于治疗前,差异具有统计学意义(P<0.05)。结论对于COVID-19确诊患者,在常规对症支持基础上给予洛匹那韦/利托那韦片联合干扰素α-2b雾化、胸腺素α1治疗,可快速改善临床症状,疗效显著。Objective To study the clinical effect of the combination of lopinavir/ritonavir tablets,atomized interferonα-2b and thymosinα1 in the treatment of Corona virus disease 2019(COVID-19).Methods Thirteen diagnosed patients with by COVID-19 enrolled in infectious diseases department of our hospital from January 2020 to February 2020 were selected.The treatment supplied the oral lopinavir/ritonavir tablets,atomized interferonα-2b and hypodermic injection of thymosinα1.The treatment effect,the improvement of clinical symptoms,the changes of laboratory indexes and HRCT scores before and after treatment were observed.Results The 13 diagnosed patients were all cured and discharged from hospital finally without any serious case occurred.The mean hospitalization days and defervescence time were 15 and 3 days respectively,and a significant reduction in cough lasted an average of 5 days.Before treatment,the LY、CRP、SAA、HRCT results of 13 diagnosed patients were obviously abnormal;after treatment,the levels of LY,CRP,SAA and HRCT scores of the patients were significantly better than those before treatment,and the differences were statistically significant(P<0.05).Conclusion For the diagnosed patients with COVID-19,except the basis of routine symptomatic support,the combination of lopinavir/ritonavir tablets,atomized interferonα-2b and thymosinα1 can rapidly improve the clinical symptoms and reveal significantly curative effect.

关 键 词：新型冠状病毒肺炎 洛匹那韦/利托那韦片 干扰素Α-2B 雾化治疗 胸腺素Α1 

分 类 号：R563.1[医药卫生—呼吸系统]